IFNA1 and Dravet syndrome: To test this notion, we evaluated IFN signaling in a research participant taking the JAK inhibitor tofacitinib (Xeljanz) for the treatment of alopecia areata, an autoimmune condition leading to hair loss that is more common in people with DS.